XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Business Acquisitions (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 20, 2021
Jul. 20, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Business Acquisition [Line Items]            
Fair value of contingent consideration     $ 168,574   $ 168,574  
Proceeds From Issuance Of Common Stock         30,121 $ 14,174
Issuance of common stock in Private Placement, net of issuance costs     294,845   294,845  
Acquisition-related costs     30,726   30,726  
Stock-based compensation expense     35,820 $ 4,992 61,790 $ 12,258
Income tax benefit from reduction in deferred tax assets valuation allowance         94,800  
Goodwill     411,533   411,533  
Omniome stock awards related to acquisition [Member]            
Business Acquisition [Line Items]            
Total cash paid $ 7,400          
Fair value of share consideration 6,300          
Fair value of contingent consideration $ 5,200          
Issuance of common stock 226,811          
Consideration $ 18,900          
Circulomics, Inc [Member]            
Business Acquisition [Line Items]            
Total cash paid   $ 29,500        
Allocation of purchase price to intangible assets   11,360        
Goodwill   $ 19,309        
Finite-Lived Intangible Assets, Gross     $ 11,360   11,360  
Omniome, Inc [Member]            
Business Acquisition [Line Items]            
Total cash paid 315,703          
Fair value of share consideration 249,435          
Fair value of contingent consideration $ 168,574          
Issuance of common stock 8,911,580          
Consideration $ 714,789          
Price Per Share $ 26.75          
Issuance of common stock in Private Placement, net of issuance costs shares 11,214,953          
Proceeds From Issuance Of Common Stock $ 294,800          
Estimated issuance costs 5,200          
Acquisition-related costs 11,600       11,600  
Stock-based compensation expense 18,900          
Income tax benefit from reduction in deferred tax assets valuation allowance 92,200          
Pro forma adjustment related to acquiree's acquisition-related costs 16,700          
Since the date of acquisition, revenues         0  
Since the date of acquisition, net loss         $ 1,600  
Goodwill 392,224          
Achievement of milestone [Member] | Omniome stock awards related to acquisition [Member]            
Business Acquisition [Line Items]            
Stock options issued by PacBio in replacement of Omniome’s unvested options 4,100          
Achievement of milestone [Member] | Omniome, Inc [Member]            
Business Acquisition [Line Items]            
Total cash paid 100,000          
Fair value of share consideration 100,000          
Fair value of contingent consideration 200,000          
In Process Research and Development, Intangible [Member] | Omniome, Inc [Member]            
Business Acquisition [Line Items]            
Allocation of purchase price to intangible assets 400,000          
Finite-Lived Intangible Assets, Gross $ 400,000